K.Drabiak, “Untangling the Promise of Human Genome Editing,”Journal of Law, Medicine and Ethics46, no. 4 (2018): 991-1009.
2.
E.Y.Adashi and I.G.Cohen, “Going Germline: Mitochondrial Replacement as a Guide to Genome Editing,”Cell164, no.5 (2016):832-835.
3.
Drabiak, supra note 1.
4.
A.B.Claiborne, R.A.English, J.P.Kahn, “Finding an Ethical Path Forward for Mitochondrial Replacement,”Science351, no.6274 (2016): 668-670.
5.
I.G.Cohen and E.Y.Adashi, “The FDA is Prohibited from Going Germlime,”Science353, no. 6289 (2016): 545-546.
6.
Id.
7.
Drabiak, supra note 1.
8.
Id.
9.
I.G.Cohen, “Circumvention Medical Tourism and Cutting Edge Medicine: The Case of Mitochondrial Replacement Therapy,”Indiana Journal of Global Legal Studies25, no. 439 (2018): 439-462.
10.
Drabiak, supra note 1.
11.
P.Lianget al., “CRISPR-Cas9-Mediated Gene Editing in Human Tripronuclear Zygotes,”Protein & Cell6, no.5 (2015): 363-372.
12.
Id.
13.
Id.
14.
Id.
15.
Id.
16.
H.Maet al., “Correction of a Pathogenic Gene Mutation in Human Embryos,”Nature548, no. 7668 (2017): 413-419.
17.
Id.
18.
Id.
19.
Id.
20.
Id.
21.
Id.
22.
Id.
23.
Id.
24.
Id.
25.
J.Steffannet al., “Could Failure in Preimplantation Genetic Diagnosis Justify Editing the Human Embryo Genome?”Cell Stem Cell22, no. 4 (2018): 481-482.
26.
Id.
27.
Id.
28.
J.Lederberg, “Biological Future of Man,” in G.Wolstenholme ed., Man and His Future (London, England: J. & A. Churchill, 1963): 263-273.
